Clinical trials
Hematologic Malignancy clinical trials
Below are recruiting hematologic malignancy clinical trials, each written for real people, not researchers. We’re tracking 287 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05092451RecruitingPhase 1/Phase 2
CD70-targeting NK cell therapy for blood cancer relapse
This study tests an immune therapy made from cord blood “NK cells” that are engineered to attack cells with a marker called CD70. It’s given after chemotherapy that reduces your blood and immune system, aiming to treat relapse or refractory (not responding) blood cancers.
Houston, TexasAges 12–80 - NCT06533579RecruitingPhase 1/Phase 2
Gene therapy for CD19-positive blood cancers
This trial tests a new gene therapy treatment for people with certain types of leukemia or lymphoma that have the CD19 marker and have not responded to other treatments. The therapy uses a virus to deliver a gene to target and kill cancer cells.
Duarte, CaliforniaAges 13–90 - NCT05443425RecruitingPhase 1
Leflunomide plus steroids for acute graft-versus-host disease
This early-phase trial tests whether adding leflunomide to standard steroid treatment can better control acute graft-versus-host disease (aGvHD) after a stem cell transplant. It may help reduce the immune reaction that damages the body while keeping treatment safe and manageable.
Duarte, CaliforniaAges 18 years+ - NCT04237623RecruitingPhase 2
GM-CSF after transplant using a matched related donor
This Phase 2 study tests whether giving a medicine called GM-CSF after an allogeneic transplant (using a matched related donor) can improve outcomes. Participants must meet health and donor-matching requirements and be eligible to safely receive the treatment and consent to the study.
Atlanta, GeorgiaAges 18–78 - NCT06712108Recruiting
Double cord blood transplant for blood cancers
This trial tests using a double (two units) umbilical cord blood transplant as a first-time donor stem cell transplant for adults with certain blood cancers or bone marrow failure diseases. It aims to see if this approach is effective and safe for patients who need a stem cell transplant but lack a fully matched donor.
Jeonju, Jeonlabuk-doAges 19 years+ - NCT07047456RecruitingPhase 3
Stem cell infusion timing and graft-versus-host disease risk in blood cancer patients
This trial looks at whether the time when stem cells are infused affects the chance of developing graft-versus-host disease (aGVHD) after a cord blood transplant. It may help find the best timing to improve outcomes for people with blood cancers.
Hefei, AnhuiAges Any age - NCT06693791RecruitingPhase 2
Romiplostim for platelet recovery after cord blood transplant
This trial tests a drug called Romiplostim N01 to help platelet levels recover faster in people with blood cancers who have had a cord blood transplant. It may reduce the need for platelet transfusions and lower bleeding risk.
Hefei, AnhuiAges 18 years+ - NCT07444268RecruitingPhase 1
Study of how DSP-5336 is processed in the body in advanced blood cancer patients
This trial looks at how your body absorbs, breaks down, and gets rid of the study drug DSP-5336 after a single dose. It is for people with advanced blood cancers that have come back or not responded to other treatments.
Chapel Hill, North CarolinaAges 18 years+ - NCT06554951Recruiting
Extracellular vesicles study in CAR-T cell therapy patients
This study looks at tiny particles called extracellular vesicles in the blood of people receiving CAR-T cell therapy for certain blood cancers. It may help researchers understand how these particles affect treatment outcomes.
Bologna, BolognaAges 18–90 - NCT04829136Recruiting
Oral fiber supplement during donor stem cell transplant
This trial tests whether taking a fiber supplement by mouth during a donor stem cell transplant helps patients tolerate treatment and potentially recover better. It’s specifically for adults who are planning a donor (allogeneic) transplant for blood cancers.
Seattle, WashingtonAges 18 years+ - NCT05893940Recruiting
Gentle physical stimulation during blood cancer transplant
This trial tests whether a low-intensity mechanical (physical) stimulation is safe and helpful for people with certain blood cancers who are about to have a transplant. It may affect how you do during or after treatment, and participation is voluntary with informed consent.
Buffalo, New YorkAges 18 years+ - NCT06895538RecruitingPhase 2/Phase 3
Comparing two immune treatments for stem cell transplant patients
This trial compares two drugs, ATLG and ATG, to see which one helps rebuild the immune system better after a stem cell transplant for blood cancer. It aims to improve recovery and reduce complications.
BeijingAges 18 years+ - NCT07573111RecruitingPhase 1
QUAIL-100 for Children With Blood Cancers After Stem Cell Transplant
This study tests a new experimental treatment called QUAIL-100 in children and young adults who have had a stem cell transplant for a serious blood cancer. The treatment is designed to help the immune system fight remaining cancer cells.
Palo Alto, CaliforniaAges 1.5 years–39 years - NCT06665100RecruitingPhase 2
Study of PUL-042 for RSV and Related Viruses in Immune-Compromised Patients
This trial tests an inhaled medicine (PUL-042) for people with blood cancers or who have had a stem cell transplant and now have a respiratory virus (parainfluenza, RSV, or human metapneumovirus). The goal is to see if the drug can help clear the virus and improve symptoms.
Duarte, CaliforniaAges 18 years+ - NCT07424833RecruitingPhase 1
Study of APG-3288 for Relapsed/Refractory Blood Cancers
This trial is testing a new drug called APG-3288 for people with certain relapsed or treatment-resistant blood cancers (like CLL/SLL, DLBCL, MCL, WM, MZL, or FL). You may qualify if you've tried at least 2 prior treatments and are looking for a new option.
Los Angeles, CaliforniaAges 18 years+ - NCT03486873RecruitingPhase 3
Study extension for people on pembrolizumab, testing long-term safety
This trial follows people with advanced tumors who are already on pembrolizumab (or similar treatment) to check long-term safety and effectiveness. It may help your care team by monitoring benefits and side effects over a longer period.
Tucson, ArizonaAges 18 years+ - NCT06395103RecruitingPhase 1/Phase 2
Zilovertamab vedotin for blood cancers and solid tumors
This trial tests a new drug called zilovertamab vedotin for children and young adults with certain blood cancers or solid tumors. The drug is designed to target and kill cancer cells, and the study will see if it is safe and effective.
Los Angeles, CaliforniaAges 6 months–25 years - NCT07724873RecruitingPhase 1/Phase 2
Withaferin A to prevent GVHD after stem cell transplant
This study tests a natural compound called Withaferin A (from ashwagandha) to see if it helps prevent graft-versus-host disease (GVHD) after a stem cell transplant. The goal is to reduce the risk of transplant complications.
Navi Mumbai, MaharashtraAges 18 years+ - NCT07719946RecruitingPhase 2
Lower dose chemo after stem cell transplant for blood cancers
This trial tests whether a lower dose of the chemotherapy drug cyclophosphamide given after a stem cell transplant is safe and effective for people with blood cancers. The goal is to reduce side effects while still helping prevent the cancer from coming back.
Navi Mumbai, MaharashtraAges 18 years+ - NCT07709195RecruitingPhase 2
Chlorophyllin to reduce mouth sores from radiation before transplant
This trial tests whether taking chlorophyllin can reduce mouth sores caused by total body radiation given before a stem cell transplant. The goal is to make the treatment easier to tolerate.
Navi Mumbai, MaharashtraAges 12–65 - NCT07101705RecruitingEarly Phase 1
Testing OriV508 for blood cancers that haven't responded to treatment
This study tests a new treatment called OriV508 for people with blood cancers (multiple myeloma or aggressive B-cell lymphoma) that have not responded to at least two previous therapies. It aims to see if the treatment is safe and helps shrink or control the cancer.
Wuhan, HubeiAges 18–75 - NCT07154823Recruiting
Blood cancer registry study for biomarker discovery
This study collects samples and health information from people with certain blood cancers to learn more about the disease and find markers that may help guide future treatments. You will not receive a treatment from this study, but you may help advance research.
Iowa City, IowaAges birth+ - NCT07257419RecruitingPhase 1
CAR T cells and stem cell transplant for leukemia and lymphoma
This trial tests giving special immune cells (CAR T cells) after a half-matched stem cell transplant. It's for children and young adults with high-risk leukemia or lymphoma that has come back or not responded to treatment.
Memphis, TennesseeAges Up to 21 years - NCT07708987RecruitingPhase 2
Withaferin-A for steroid-resistant graft-versus-host disease
This trial tests a plant-based medicine, Withaferin-A, in people whose graft-versus-host disease (GVHD) after a stem cell transplant has not responded to steroid treatment. GVHD is a condition where donated immune cells attack the body; this study aims to see if Withaferin-A can help control it.
Navi Mumbai, MaharashtraAges 12–65
Hear when a new Hematologic Malignancy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for hematologic malignancy?
- Yes. Clin2 currently lists 287 recruiting hematologic malignancy studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a hematologic malignancy trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a hematologic malignancy trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.